Literature DB >> 10952610

TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy.

M Perilli1, B Segatore, M R de Massis, M L Riccio, C Bianchi, A Zollo, G M Rossolini, G Amicosante.   

Abstract

A new natural TEM-2 derivative, named TEM-72, was identified in a Proteus mirabilis strain and in a Morganella morganii strain isolated in Italy in 1999. Compared to TEM-1, TEM-72 contains the following amino acid substitutions: Q39K, M182T, G238S, and E240K. Kinetic analysis showed that TEM-72 exhibits an extended-spectrum activity, including activity against oxyimino-cephalosporins and aztreonam. Expression of bla(TEM-72) in Escherichia coli was capable of decreasing the host susceptibility to the above drugs.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952610      PMCID： PMC90100          DOI： 10.1128/AAC.44.9.2537-2539.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

2.  Automated analysis of enzyme inactivation phenomena. Application to beta-lactamases and DD-peptidases.

Authors:  F De Meester; B Joris; G Reckinger; C Bellefroid-Bourguignon; J M Frère; S G Waley
Journal:  Biochem Pharmacol       Date:  1987-07-15       Impact factor: 5.858

3.  Interactions of new plasmid-mediated beta-lactamases with third-generation cephalosporins.

Authors:  R Labia; A Morand; K Tiwari; J Sirot; D Sirot; A Petit
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

4.  Diversity of TEM mutants in Proteus mirabilis.

Authors:  R Bonnet; C De Champs; D Sirot; C Chanal; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Complete amino acid sequence of p453-plasmid-mediated PIT-2 beta-lactamase (SHV-1).

Authors:  M Barthélémy; J Peduzzi; R Labia
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

6.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

7.  Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322.

Authors:  J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

8.  TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases.

Authors:  P A Bradford; N V Jacobus; N Bhachech; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 9.  Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.

Authors:  J Sirot; C Chanal; A Petit; D Sirot; R Labia; G Gerbaud
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

10.  Citrobacter diversus ULA27 produces two forms of a chromosomal beta-lactamase.

Authors:  B Oliva; M C Marinucci; G Amicosante; A Oratore; P M Bennett
Journal:  J Antimicrob Chemother       Date:  1987-07       Impact factor: 5.790
View more
  16 in total

1.  New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates.

Authors:  C de Champs; C Monne; R Bonnet; W Sougakoff; D Sirot; C Chanal; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Emerging extended-spectrum beta-lactamases in Proteus mirabilis.

Authors:  Laura Pagani; Roberta Migliavacca; Lucia Pallecchi; Cecilia Matti; Ernesto Giacobone; Gianfranco Amicosante; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

4.  Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey.

Authors:  Mariagrazia Perilli; Emanuela Dell'Amico; Bernardetta Segatore; Maria Rosaria de Massis; Ciro Bianchi; Francesco Luzzaro; Gian Maria Rossolini; Antonio Toniolo; Giuseppe Nicoletti; Gianfranco Amicosante
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2002-03       Impact factor: 4.562

Review 6.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Experimental prediction of the natural evolution of antibiotic resistance.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2003-04       Impact factor: 4.562

8.  Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants.

Authors:  William A Schroeder; Troy R Locke; Susan E Jensen
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

9.  A new TEM-derived extended-spectrum beta-lactamase (TEM-91) with an R164C substitution at the omega-loop confers ceftazidime resistance.

Authors:  Hiroshi Kurokawa; Naohiro Shibata; Yohei Doi; Keigo Shibayama; Kazunari Kamachi; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  TEM-187, a new extended-spectrum β-lactamase with weak activity in a Proteus mirabilis clinical strain.

Authors:  Stéphane Corvec; Racha Beyrouthy; Lise Crémet; Guillaume Ghislain Aubin; Frédéric Robin; Richard Bonnet; Alain Reynaud
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.